- Conditions
- Pancreatic Cancer
- Interventions
- Cyclophosphamide, Cyclophosphamide Pill, GVAX Pancreas Vaccine
- Drug · Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–14
of 14
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Breast Cancer
- Interventions
- Cohort 1 neo-adjuvant, Cohort 2 neo-adjuvant, Cohort 1 adjuvant, Cohort 2 adjuvant
- Drug
- Lead sponsor
- William Sikov MD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 5
- States / cities
- Duarte, California • New Haven, Connecticut • Providence, Rhode Island
- Conditions
- Breast Cancer
- Interventions
- Radiation
- Radiation
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 19 Years to 99 Years · Female only
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 3
- States / cities
- New York, New York
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Dendritic Cell (DC) Injections, Radiation therapy, Complete Resection - Surgery for tumor removal
- Biological · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas
- Interventions
- Vemurafenib
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Oakland, California • San Diego, California + 15 more
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Interventions
- LOXO-292
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 857 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 41
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 33 more
- Conditions
- Prostate Cancer
- Interventions
- sargramostim, immunohistochemistry staining method, immunological diagnostic method, laboratory biomarker analysis, conventional surgery, neoadjuvant therapy
- Biological · Other · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Prostate Cancer
- Interventions
- Everolimus, conventional surgery
- Drug · Procedure
- Lead sponsor
- Jorge A. Garcia, MD
- Other
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- BNT116, Cemiplimab, Docetaxel, Carboplatin, Paclitaxel, BNT316, anti-B7-H3 antibody conjugated to topoisomerase I inhibitor, anti-HER3 antibody conjugated to topoisomerase I inhibitor, Bispecific antibody for PD-L1 and VEGF-A, Osimertinib, ALK-inhibitor or RET-inhibitor
- Biological · Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 6
- States / cities
- Lexington, Kentucky • Louisville, Kentucky • Baltimore, Maryland + 3 more
- Conditions
- Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
- Interventions
- Lifileucel, LN-145, Pembrolizumab, LN-145-S1, Ipilimumab, Nivolumab, Nivolumab-relatlimab, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Pemetrexed
- Biological · Drug
- Lead sponsor
- Iovance Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 20
- States / cities
- La Jolla, California • Los Angeles, California • Denver, Colorado + 15 more
- Conditions
- Melanoma
- Interventions
- Excision of clinically detected lymph node metastasis before any systemic therapy, Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy
- Procedure
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Ann Arbor, Michigan + 4 more
- Conditions
- Pancreatic Cancer
- Interventions
- Cyclophosphamide, GVAX Pancreas Vaccine, Stereotactic Body Radiation, FOLFIRINOX
- Drug · Biological · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 76 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Bladder Cancer
- Interventions
- Nivolumab, Nivolumab/Lirilumab
- Drug
- Lead sponsor
- PrECOG, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 8
- States / cities
- Tampa, Florida • New York, New York • The Bronx, New York + 5 more
- Conditions
- Solid Tumor, Unresectable or Metastatic Melanoma
- Interventions
- CX-072, Ipilimumab
- Drug
- Lead sponsor
- CytomX Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 14
- States / cities
- Duarte, California • Los Angeles, California • Coeur d'Alene, Idaho + 8 more